A delegation of representatives of the Danish Novo Nordisk pharmaceutical company arrived in Israel this week, to explore opportunities for industrial cooperation and investments.
Novo Nordisk is the largest industrial company in Denmark, with a sales turnover of $2.5 billion, and employing 14,000 workers. The company specializes in developing bioethical medications, and is a market leader in the production of insulin and enzymes.
The delegation will meet Chief Scientist Dr Orna Berry, the director of investments promotion unit Max Livnat, established biotechnology companies, start ups, incubators, research institutes and universities, together with venture capital funds specializing in biotechnology.
Published by Israel's Business Arena June 29, 1998.